دورية أكاديمية
أعرض في EDS

Clinical analysis of pathologic complete responders in advanced-stage ovarian cancer.

التفاصيل البيبلوغرافية
العنوان: Clinical analysis of pathologic complete responders in advanced-stage ovarian cancer.
المؤلفون: LaFargue CJ; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States of America., Handley KF; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States of America., Fleming ND; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States of America., Nick AM; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States of America., Chelariu-Raicu A; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States of America., Fellman B; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, United States of America., Castellano T; Department of Gynecologic Oncology, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States of America., Ogasawara A; Department of Gynecologic Oncology, Saitama Medical University International Medical Center, Saitama, Japan., Hom-Tedla M; Department of Gynecologic Oncology, University of Southern California, Los Angeles, CA, United States of America., Blake EA; Department of Gynecologic Oncology, University of Southern California, Los Angeles, CA, United States of America., da Costa AABA; Department of Medical Oncology, A.C. Camargo Cancer Center, Sao Paulo, Brazil., Crim AK; Department of Gynecologic Oncology, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States of America., Rauh-Hain A; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States of America., Westin SN; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States of America., Coleman RL; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States of America., Matsuo K; Department of Gynecologic Oncology, University of Southern California, Los Angeles, CA, United States of America., Baiocchi G; Department of Gynecologic Oncology, A.C. Camargo Cancer Center, Sao Paulo, Brazil., Hasegawa K; Department of Gynecologic Oncology, Saitama Medical University International Medical Center, Saitama, Japan., Moore K; Department of Gynecologic Oncology, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States of America., Sood AK; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States of America. Electronic address: asood@mdanderson.org.
المصدر: Gynecologic oncology [Gynecol Oncol] 2022 Apr; Vol. 165 (1), pp. 82-89. Date of Electronic Publication: 2022 Feb 23.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Academic Press Country of Publication: United States NLM ID: 0365304 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1095-6859 (Electronic) Linking ISSN: 00908258 NLM ISO Abbreviation: Gynecol Oncol Subsets: MEDLINE
أسماء مطبوعة: Original Publication: New York, Academic Press.
مواضيع طبية MeSH: Neoadjuvant Therapy* , Ovarian Neoplasms*/drug therapy , Ovarian Neoplasms*/surgery, Carcinoma, Ovarian Epithelial/drug therapy ; Chemotherapy, Adjuvant ; Female ; Humans ; Neoplasm Staging ; Neoplasm, Residual/pathology ; Retrospective Studies
مستخلص: Objective: To determine the clinical characteristics of patients who attained pathologic complete response (pCR) after neoadjuvant chemotherapy (NACT) and to identify specific predictive or prognostic factors associated with pCR.
Methods: Two distinct populations of patients who underwent NACT followed by interval tumor reductive surgery (TRS) were used in this retrospective study. The first contained 472 patients from a single institution. The second contained only pCR patients (67); those identified from population one, plus 44 obtained through collaborative institutions. Cox analysis and log-rank tests were performed to assess associations between clinical characteristics and pCR outcome, recurrence-free survival (RFS), and overall survival (OS).
Results: The median RFS and OS in our pCR-only population was 24.2 and 80.8 months, respectively, with a median follow-up time of 32.4 months. In our single institution population, 23 patients attained pCR (4.9%) and had longer RFS compared to non-pCR patients with viable microscopic, optimal, or suboptimal residual disease (24.3 vs. 12.1 vs. 11.6 vs. 9.6 months, p = 0.025, 0.012, 0.008, respectively), and longer OS compared to those with optimal or suboptimal residual disease (54.5 vs. 29.4 vs. 25.7 months, p = 0.027, 0.007, respectively). Patients were more than three-fold likely to attain pCR if their CA125 value was normal at the time of surgery (OR 3.54, 95% CI: 1.14-11.05, p = 0.029).
Conclusions: Women with pCR after NACT have significantly longer RFS compared to those with residual viable tumor at the time of interval tumor-reductive surgery, and CA125 is plausible biomarker for identifying these extreme responders preoperatively.
Competing Interests: Declaration of Competing Interest During the conduct of the study, BF reports grants from NIH; KFH reports grants from CPRIT; AKS reports grants from NIH; and SNW reports grants from NIH and GOG Foundation. Outside the submitted work, RLC reports grants and personal fees from AstraZeneca, grants from Merck, personal fees from GSK, grants and personal fees from Clovis, grants and personal fees from Genmab, grants and personal fees from Roche/Genentech, grants and personal fees from Janssen, personal fees from Agenus, personal fees from Regeneron, and personal fees from OncoQuest; NDF reports personal fees from Tesaro, personal fees from BMS/Pfizer, and personal fees from GSK; KH reports grants and personal fees from MSD, grants from Daiichi-Sankyo, personal fees from Chugai, grants and personal fees from Takeda, personal fees from Mochida, personal fees from Eisai, grants from Abbott, and grants from Ono; CJL reports personal fees from Agenus; KMatsuo reports other from Chugai; KMoore reports personal fees and other from Astra Zeneca, grants, personal fees and other from Genentech/Roche, grants, personal fees and other from Immunogen, grants, personal fees and other from Clovis, grants, personal fees and other from GSK/Tesaro, other from Pfizer, personal fees from Aravive, personal fees from VBL Therapeutics, personal fees from Onco Med, grants and other from Lilly, personal fees from Eisai, personal fees from Vavotar, personal fees from Abbvie, personal fees from Tarveda, personal fees from Myriad, personal fees from Rubius, personal fees from Elevar, personal fees from Merck, personal fees from Mersana, personal fees from Sorrento, and personal fees from OncXerna; AKS reports grants from M-Trap, other from Biopath, personal fees from Merck, personal fees from Kiyatec, and personal fees from Astra Zeneca; SNW reports grants and personal fees from AstraZeneca, grants and personal fees from Clovis Oncology, grants and personal fees from GSK/Tesaro, grants and personal fees from Roche/Genentech, grants and personal fees from Novartis, personal fees from Merck, personal fees from Pfizer, personal fees from Eisai, grants from Cotinga Pharmaceuticals, grants from Bayer, grants from ArQule, personal fees from CIrculogene, personal fees from Agenus, grants from Mereo, and grants from Bio-Path. The remaining authors report no conflict of interest.
(Copyright © 2022 Elsevier Inc. All rights reserved.)
References: Gynecol Oncol. 2006 Nov;103(2):559-64. (PMID: 16714056)
Int J Gynecol Cancer. 2020 Nov;30(11):1657-1664. (PMID: 33028623)
Gynecol Oncol. 2010 Oct;119(1):7-17. (PMID: 20692025)
N Engl J Med. 2010 Sep 2;363(10):943-53. (PMID: 20818904)
Eur J Cancer. 2020 May;130:114-125. (PMID: 32179446)
Oncotarget. 2016 Sep 13;7(37):60647-60656. (PMID: 27447966)
Int J Gynecol Cancer. 2020 Jan;30(1):67-73. (PMID: 31754067)
Gynecol Oncol. 2021 Jan;160(1):32-39. (PMID: 33196436)
Breast Cancer Res Treat. 2014 Apr;144(2):223-32. (PMID: 24557340)
Cancer J. 2012 Jul-Aug;18(4):320-7. (PMID: 22846732)
Gynecol Oncol. 2003 Aug;90(2):390-6. (PMID: 12893206)
Obstet Gynecol. 2006 Jan;107(1):77-85. (PMID: 16394043)
Lancet. 2015 Jul 18;386(9990):249-57. (PMID: 26002111)
J Clin Oncol. 2012 Jul 20;30(21):2654-63. (PMID: 22711857)
J Surg Oncol. 2019 Sep;120(4):779-785. (PMID: 31283034)
Gynecol Oncol. 2013 Dec;131(3):531-4. (PMID: 24096109)
Nature. 2012 Oct 4;490(7418):61-70. (PMID: 23000897)
Lancet. 2019 Dec 7;394(10214):2084-2095. (PMID: 31791688)
CA Cancer J Clin. 2018 Jul;68(4):284-296. (PMID: 29809280)
CA Cancer J Clin. 2019 Jan;69(1):7-34. (PMID: 30620402)
Am J Obstet Gynecol. 2014 Dec;211(6):632.e1-8. (PMID: 24954656)
N Engl J Med. 2012 Feb 16;366(7):610-8. (PMID: 22335738)
Lancet Oncol. 2013 Sep;14(10):1020-6. (PMID: 23948349)
Gynecol Oncol. 2013 Sep;130(3):499-504. (PMID: 23747328)
J Clin Oncol. 2016 Nov 10;34(32):3854-3863. (PMID: 27601552)
Lancet. 2014 Jul 12;384(9938):164-72. (PMID: 24529560)
معلومات مُعتمدة: K08 CA234333 United States CA NCI NIH HHS; P30 CA016672 United States CA NCI NIH HHS; P50 CA217685 United States CA NCI NIH HHS; R35 CA209904 United States CA NCI NIH HHS
تواريخ الأحداث: Date Created: 20220226 Date Completed: 20220405 Latest Revision: 20230402
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC8969169
DOI: 10.1016/j.ygyno.2022.02.006
PMID: 35216808
قاعدة البيانات: MEDLINE
الوصف
تدمد:1095-6859
DOI:10.1016/j.ygyno.2022.02.006